Screening for prostate cancer with prostate-specific antigen: Beware the biases

Clinica Chimica Acta

Volumn 315, Issue 1-2, 2002, Pages 71-97

  Bunting, Peter S ^a,b  

^a DYNACARE LABORATORIES   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bias; Evidence based medicine; Neoplasm; Prostate specificantigen; Screen

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN;

AUTOPSY; BEAM THERAPY; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER RISK; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; HEALTH CARE COST; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SCREENING TEST; TREATMENT OUTCOME;

AGE FACTORS; AGED; BIAS (EPIDEMIOLOGY); BIOPSY; DIAGNOSTIC ERRORS; EVIDENCE-BASED MEDICINE; GUIDELINES; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PHYSICAL EXAMINATION; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REFERENCE VALUES; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0036133012     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(01)00717-3     Document Type: Review

References (181)

1. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II. Early detection strategies
2. Report prepared for the health technology assessment panelof the NHS executive on the diagnosis, management, treatment andcosts of prostate cancer in England and Wales
3. Diagnosis and management of early prostate cancer. Report of a British Association of Urological Surgeons Working Party
4. American Cancer Society guideline for the early detection of prostate cancer: Update 1997
5. Screening for prostate cancer. Clinical Guideline: Part III
6. PSA screening: A public health dilemma
7. Is screening for prostate cancer the current gold standard?- Yes
8. Is screening for prostate cancer the current gold standard?- No
9. Ethics of a prostate cancer screening trial
10. Incidence of prostate cancer diagnosis in the eras beforeand after serum prostate-specific antigen testing
11. Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization and futureintentions
12. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European Randomized Study of Screening forProstate Cancer, Rotterdam
13. Rationale for randomised trials of prostate cancer screening
14. Cancer of the prostate: A nutritional disease?
15. Diet, androgens, oxidative stress and prostate cancer susceptibility
16. Screening for prostate cancer. The challenge of promoting informed decision making in the absence of definitive evidence ofeffectiveness
17. Family history facilitates the early diagnosis of prostate carcinoma
18. Familial prostate cancer: A different disease?
19. Racial differences in a prostate cancer screening study
20. Prostate-specific antigen (PSA) and PSA density: Racial differences in men without prostate cancer
21. Age-specific reference ranges for serum prostate-specific antigen in black men
22. Racial differences in operating characteristics of prostate cancer screening tests
23. Correlation of pathologic findings with progression after radical retropubic prostatectomy
24. An assessment of radical prostatectomy. Time trends, geographic variation and outcomes
25. Trends in patterns of care for prostate cancer, 1974-1983: Results of survey by the American College of Surgeons
26. What is the role of early detection and screening in cancer control?
27. Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?
28. Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate
29. Cancer screening. Degrees of proof and practical application
30. Appraising organized screening programs for genetic susceptibility testing
31. Prostate-specific antigen testing to screen for prostate cancer
32. Prostate cancer screening: Promise and peril - A review
33. Prostate cancer: To screen or not to screen?
34. Are increasing 5-y survival rates evidence of successagainst cancer?
35. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients
36. Prostate cancer: 2. Natural history
37. Impact of prostate-specific antigen screening on the natural history of prostate cancer
38. Analysis of recent trends in prostate cancer incidence and mortality
39. Early detection of prostate cancer: Part I. Priorprobability and effectiveness of tests
40. Screening for prostate cancer
41. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men
42. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostatespecific antigen
43. Progress and problems in screening for carcinoma of the prostate
44. Experience with the German annual preventive checkup examination
45. Cancer of the prostate gland. Results of early diagnosis and therapy undertaken for cure of the disease
46. Evaluation of annual examination in the detection of cancer: Special reference to cancer of the gastrointestinal tract,prostate, breast, and female reproductive tract
47. Prostate cancer: Comparison of transrectal US and digital rectal examination for screening
48. A screening study of prostate cancer in high risk families
49. Relative sensitivity and specificity of serum prostate specific antigen (PSA) concentration compared with age referencedPSA, PSA density and PSA change
50. An evaluation of serial digital rectal examinations in screening for prostate cancer
51. Impact of routine screening for adenocarcinoma of the prostate on stage distribution
52. Screening for carcinoma of the prostate. Rectal examination, and enzymatic and radioimmunologic measurement of serum acid phosphatase compared
53. Digital rectal examination to screen for prostatic cancer
54. Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer
55. Is there still a role for prostatic acid phosphatase? CSCC position statement
56. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
57. Prostate specific antigen: A decade of discovery - What we have learned and where we are going
58. The use of percent free prostate specific antigen forstaging clinically localized prostate cancer
59. An evaluation of prostate-specific antigen as a screening test for prostate cancer
60. Measurement of prostate specific antigen in serum as a screening test for prostate cancer
61. Comparison between digital rectal examination, prostate specific antigen and transrectal ultrasound in symptomatic patients
62. Detection of prostate cancer by digital rectal exam, prostate specific antigen, and transrectal ultrasonography
63. Serum prostate specific antigen and prostate pathology inmen having simple prostatectomy
64. The relationship of prostate specific antigen to digital rectal examination and transrectal ultrasonography
65. Early detection program for prostate cancer: Results and identification of high-risk population
66. Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer
67. Screening for carcinoma of the prostate with prostate specific antigen
68. Screening for prostatic carcinoma with prostate specific antigen
69. Systematic prostatic biopsies in 100 men with no suspicionof cancer on digital rectal examination
70. The use of prostate-specific antigen and free/total prostate specific antigen in the diagnosis of localized prostate cancer
71. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen
72. Systematic sextant biopsies in 651 patients referred for prostate evaluation
73. Diagnosis of prostatic carcinoma: The yield of serumprostate specific antigen, digital rectal examination andtransrectal ultrasonography
74. Detection of organ-confined prostate cancer is increased through prostate specific antigen based screening
75. Second Standard Conference on international standardization of prostate-specific antigen immunoassays: September 1 and 2, 1994
76. Reference reagents for prostate-specific antigen (PSA): Establishment of the First International Standards for free PSA and PSA (90:10)
77. WHO First International Standards for prostate-specific antigen: The beginning of the end for assay discrepancies?
78. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer
79. Prostate-specific antigen testing for early diagnosis of prostate cancer: Formulation of guidelines
80. Prostate specific antigen: A decade of discovery - What we have learned and where we are going
81. Etiology and diagnosis of prostate cancer: What's new?
82. Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer
83. Clinical value of human glandular kallikrein and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen concentrations 3.0 ng/mL or greater
84. Serum prostate-specific antigen in a community-based population of healthy men
85. Longitudinal evaluation of prostate-specific antigen concentrations in men with and without prostate diseases
86. A guide to the interpretation of serum prostate specific antigen concentrations
87. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: Critical analysis of two different test populations
88. Free and total prostate-specific antigen in a screened population
89. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer
90. Complexed PSA: The wave of the future
91. Ratio of free or complexed prostate-specific antigen (PSA)to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
92. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer
93. The stability of free and bound prostate-specific antigen
94. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: A prospective multicenterclinical trial
95. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network
96. Rational PSA screening strategies for prostate cancer: Computer simulations of age ranges, PSA cutoffs, and testing intervals
97. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer
98. Longitudinal screening for prostate cancer with prostate-specific antigen
99. Diagnosis of prostatic carcinoma: The yield of serum prostate-specific antigen, digital rectal examination and transrectal ultrasound
100. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values
101. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer
102. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: Impact on cancer detection
103. Clinical prognostic criteria for later diagnosis of prostate carcinoma in patients with isolated prostatic intraepithelial neoplasia
104. Screening for prostate cancer: An analysis of the early experience
105. Pathologic and clinical findings to predict tumor extent of nonpalpable (Stage T1c) prostate cancer
106. Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer
107. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening
108. The results of a five-y early prostate cancer detection intervention
109. PSA screening - Current controversy
110. Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997
111. Screening for prostate cancer - Necessity or nonsense?
112. Heterogeneity of prostate cancer in radical prostatectomy specimens
113. Positive biopsy rate consistently increases with age at the same prostate-specific antigen concentration in patients with normal digital rectal examination
114. The influence of age and prostate specific antigen on the chance of curable prostate cancer among men with non-palpable disease
115. Staging of prostate cancer
116. Tumor volume and prostate specific antigen: Implications for early detection and defining a window of curability
117. Prostate cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimens
118. Combination of prostate-specific antigen, clinical stage, and Gleason Score to predict pathological stage of localized prostate cancer
119. Estimation of prostate cancer probability by logistic regression: Free and total prostate specific antigen, digital rectal examination and heredity are significant variables
120. Use of artificial neural networks in the clinical staging of prostate cancer: Implications for prostate brachytherapy
121. Molecular and cellular biology of the prostate: Is it clinically relevant?
122. Tumor-suppressor genes in prostatic oncogenesis: A positional approach
123. Identification of genetic markers for prostatic cancer progression
124. Plasma insulin-like growth factor and prostate cancer risk: A prospective study
125. Low p27 expression predicts poor disease-free survival in patients with prostate cancer
126. Genome wide scan for prostate cancer aggressiveness loci
127. Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX
128. Combined analysis of hereditary prostate cancer linkage to 1q24-25: Results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics
129. Prostate-specific membrane antigen (PSMA): Current benefits and future value
130. Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction
131. Prognostic factors in prostate cancer. College of American Pathologists consensus statement 1999
132. Comparison of recommendations of urologists and radiation oncologists for treatment of clinically localized prostate cancer
133. Population based study of long term survival in patients with clinically localised prostate cancer
134. A structured literature review of treatment for localized prostate cancer
135. PSA screening - Current controversy
136. Prostate cancer: 6. Surgical treatment of localized disease
137. Prostate cancer: 7. Radiation therapy for localized disease
138. Screening for prostate cancer. A decision analytic view
139. A decision analysis of alternative treatment strategies for clinically localized prostate cancer
140. Quality-of-life outcomes for men with prostate carcinoma detected by screening
141. Prostate cancer: A challenge for screening
142. The changing pattern of prostate cancer at the time of diagnosis: Characteristics of screen detected prostate cancer in a population based screening study
143. Prostate carcinoma trends in three counties in Sweden 1987-1996. Results from a population-based national cancer register
144. Prostate cancer screening in the Tyol, Austria: Experience and results
145. Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyol, Austria
146. Downward trend in prostate cancer mortality in Quebec and Canada
147. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the U.S.
148. Prostate-specific antigen utilization in Ontario: Extent of testing in patients with and without cancer
149. Cancer surveillance series: Interpreting trends in prostate cancer: Part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality and survival rates
150. Cancer surveillance series: Interpreting trends in prostate cancer: Part III. Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality
151. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer
152. PSA screening for prostate cancer: The current controversy
153. Economics of screening for carcinoma of the prostate
154. Prostate cancer screening. Appropriate choices?
155. Early detection of prostate cancer. Part II: Estimating the risks, benefits and costs
156. The economic burden of prostate cancer: Forecasts from the Montreal Prostate Model
157. The economics of prostate cancer screening
158. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen
159. Prostate cancer: 12. The economic burden
160. Attitudes and practices of primary care physicians for prostate cancer screening
161. Attitudes of European urologists to early prostatic carcinoma II. Attitude to therapy and to screening examinations
162. Decision aids for patients facing health treatment or screening decisions: Systematic review
163. What questions do patients with curable prostate cancer want answered?
164. The impact of informed consent on patient interest in prostate-specific antigen screening
165. A randomized controlled trial of shared decision making for prostate cancer screening
166. The use of prostate specific antigen for prostate cancer screening: A managed care perspective
167. PSA screening: A view from the front lines
168. PSA screening: The bottom line
169. Prostate cancer screening. Why the controversy?